Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins.
暂无分享,去创建一个
Leigh Zawel | Santosh Kesari | David S Ziegler | Andrew L Kung | S. Kesari | L. Zawel | A. Kung | M. Lemieux | D. Ziegler | Monish Jain | R. Wright | Renee D Wright | Madeleine E Lemieux | Mary A Tran | Monish Jain | Mary A. Tran
[1] A. Kung,et al. Anti-apoptosis mechanisms in malignant gliomas. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] W. Sellers,et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. , 2007, Cancer research.
[3] David L. Vaux,et al. IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis , 2007, Cell.
[4] Vishva M. Dixit,et al. IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis , 2007, Cell.
[5] Lee M Ellis,et al. Targeted therapy trials: approval strategies, target validation, or helping patients? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Hongye Liu,et al. Olig2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant Glioma , 2007, Neuron.
[7] M. Berens,et al. Molecular targets of glioma invasion , 2007, Cellular and Molecular Life Sciences.
[8] N. Munshi,et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). , 2004, Blood.
[9] A. Kung. Practices and pitfalls of mouse cancer models in drug discovery. , 2007, Advances in cancer research.
[10] Howard A. Fine,et al. Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.
[11] C. Dominici,et al. Increased sensitivity to the platelet‐derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF‐BB‐mediated signaling and STI571‐induced Akt inactivation , 2006, Journal of cellular physiology.
[12] D. Bodurka,et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. , 2006, Gynecologic oncology.
[13] Jayant P. Menon,et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. , 2006, Cancer cell.
[14] D. Bigner,et al. Recent advances in the treatment of malignant astrocytoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Thomas D. Wu,et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.
[16] Ning Lin,et al. Noninvasive Bioluminescence Imaging of Luciferase Expressing Intracranial U87 Xenografts: Correlation with Magnetic Resonance Imaging Determined Tumor Volume and Longitudinal Use in Assessing Tumor Growth and Antiangiogenic Treatment Effect , 2006, Neurosurgery.
[17] E. Kohmura,et al. Synthetic Smac peptide enhances the effect of etoposide-induced apoptosis in human glioblastoma cell lines , 2006, Journal of Neuro-Oncology.
[18] S. Fulda,et al. Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. , 2005, Cancer research.
[19] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[20] Stephen W. Fesik,et al. Promoting apoptosis as a strategy for cancer drug discovery , 2005, Nature Reviews Cancer.
[21] C. Duckett,et al. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. , 2005, The Journal of clinical investigation.
[22] T. Mikkelsen,et al. Angiogenesis and apoptosis in glioma: Two arenas for promising new therapies , 2005, Journal of cellular biochemistry.
[23] M. Decamp,et al. The Role of Surgery in N2 Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[24] F. McCormick,et al. Killing time for cancer cells , 2005, Nature Reviews Cancer.
[25] M. Berger,et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.
[26] J. Pollard,et al. ARC, an apoptosis suppressor limited to terminally differentiated cells, is induced in human breast cancer and confers chemo- and radiation-resistance , 2005, Cell Death and Differentiation.
[27] M. Crow,et al. Apoptosis repressor with caspase recruitment domain (ARC) is expressed in cancer cells and localizes to nuclei , 2005, FEBS letters.
[28] D. Graves,et al. FOXO1 Functions as a Master Switch That Regulates Gene Expression Necessary for Tumor Necrosis Factor-induced Fibroblast Apoptosis* , 2005, Journal of Biological Chemistry.
[29] R. Kiss,et al. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Donna Neuberg,et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.
[31] L. Ellis,et al. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] R. Henkelman,et al. Identification of human brain tumour initiating cells , 2004, Nature.
[33] M. Weller,et al. Apoptosis in Gliomas: Molecular Mechanisms and Therapeutic Implications , 2004, Journal of Neuro-Oncology.
[34] Xiaodong Wang,et al. A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell Death , 2004, Science.
[35] M. Crow,et al. Apoptosis Repressor with Caspase Recruitment Domain Protects against Cell Death by Interfering with Bax Activation* , 2004, Journal of Biological Chemistry.
[36] A. Gajjar,et al. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. , 2004, The oncologist.
[37] D. Fabbro,et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. , 2004, Cancer cell.
[38] D. Matei,et al. Imatinib Mesylate (Gleevec) Inhibits Ovarian Cancer Cell Growth through a Mechanism Dependent on Platelet-Derived Growth Factor Receptor α and Akt Inactivation , 2004, Clinical Cancer Research.
[39] Allan H Friedman,et al. Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Andrew L Kung,et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[41] W. Roa,et al. X-linked inhibitor regulating TRAIL-induced apoptosis in chemoresistant human primary glioblastoma cells. , 2003, Clinical and investigative medicine. Medecine clinique et experimentale.
[42] D. Jo,et al. Down‐regulation of ARC contributes to vulnerability of hippocampal neurons to ischemia/hypoxia , 2003, FEBS Letters.
[43] R. Jenkins,et al. Recent advances in the molecular genetics of primary gliomas , 2003, Current opinion in oncology.
[44] G. Gores,et al. Synthetic Smac/DIABLO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ * , 2002, The Journal of Biological Chemistry.
[45] A. Chakravarti,et al. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. , 2002, Cancer research.
[46] P. Black,et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] Michael Weller,et al. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo , 2002, Nature Medicine.
[48] P. Black,et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. , 2000, Cancer research.
[49] S. Honsawek,et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[50] I. Fidler,et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. , 2000, Cancer research.
[51] A. Schally,et al. Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice. , 2000, Neoplasia.
[52] John Calvin Reed,et al. Purification and use of recombinant inhibitor of apoptosis proteins as caspase inhibitors. , 2000, Methods in enzymology.
[53] D. Groothuis,et al. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. , 2000, Neuro-oncology.
[54] T. Tsuruo,et al. A human IAP-family gene, apollon, expressed in human brain cancer cells. , 1999, Biochemical and biophysical research communications.
[55] A. Merlo,et al. Frequent Co‐Alterations of TP53, p16/CDKN2A, p14ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines. , 1999, Brain pathology.
[56] S. Kügler,et al. Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma , 1999, Cell Death and Differentiation.
[57] S. Chen,et al. ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[58] A. Guha,et al. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop , 1995, International journal of cancer.
[59] S. Shamah,et al. Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells , 1993, Molecular and cellular biology.
[60] E. Oldfield,et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. , 1992, Cancer research.
[61] C. Heldin,et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. , 1992, Cancer research.
[62] S. Gammeltoft,et al. Expression of two types of receptor for insulin-like growth factors in human malignant glioma. , 1988, Cancer research.